Design, synthesis of benzimidazole tethered 3,4-dihydro-2H-benzo[e] [1, 3] oxazines as anticancer agents

Al-Ghorbani M, Bushra Begum A, Zabiulla Z et al (2015) Piperazine and morpholine: synthetic preview and pharmaceutical applications. Res J Pharm Technol 8:611–628. https://doi.org/10.5958/0974-360X.2015.00100.6 Sawyer TK (2007) Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy. Cancer. https://doi.org/10.1007/7355_2006_010 Mathur G, Nain S, Sharma PK (2015) Cancer: an overview. Acad J Cancer Res 8(1):1–9 Hassanpour SH, Dehghani M (2017) Review of cancer from perspective of molecular. J Cancer Res Pract 4:127–129. https://doi.org/10.1016/j.jcrpr.2017.07.001 Mallikanti V, Thumma V, Veeranki KC et al (2022) Synthesis, cytotoxicity, molecular docking and ADME assay of novel morpholine appended 1,2,3-triazole analogues. ChemistrySelect 7:e202204020. https://doi.org/10.1002/slct.202204020 Ruddarraju RR, Murugulla AC, Kotla R et al (2017) Design, synthesis, anticancer activity and docking studies of theophylline containing 1,2,3-triazoles with variant amide derivatives. Medchemcomm 8:176–183. https://doi.org/10.1039/C6MD00479B Sun C, Chen C, Xu S et al (2016) Synthesis and anticancer activity of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives bearing chromone moiety. Bioorg Med Chem 24:3862–3869. https://doi.org/10.1016/j.bmc.2016.06.032 Organization WH Cancer. http://www.who.int/cancer/en/. Accessed 9 Oct 2018 Lee CY, Chew EH, Go ML (2010) Functionalized aurones as inducers of NAD(P)H:quinone oxidoreductase 1 that activate AhR/XRE and Nrf2/ARE signaling pathways: Synthesis, evaluation and SAR. Eur J Med Chem 45:2957–2971. https://doi.org/10.1016/j.ejmech.2010.03.023 Vásquez D, Rodríguez JA, Theoduloz C et al (2010) Studies on quinones. Part 46. Synthesis and in vitro antitumor evaluation of aminopyrimidoisoquinolinequinones. Eur J Med Chem 45:5234–5242. https://doi.org/10.1016/j.ejmech.2010.08.040 Arcamone F, Cassinelli G, Fantini G et al (1969) Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic from S Peucetius var caesius. Biotechnol Bioeng 11:1101–1110. https://doi.org/10.1002/bit.260110607 Cortés-Funes H, Coronado C (2007) Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 7:56–60. https://doi.org/10.1007/s12012-007-0015-3 Robledo-Cadena DX, Gallardo-Pérez JC, Dávila-Borja V et al (2020) Non-steroidal anti-inflammatory drugs increase cisplatin, paclitaxel, and doxorubicin efficacy against human cervix cancer cells. Pharmaceuticals 13:1–25. https://doi.org/10.3390/ph13120463 Rushing DA, Raber SR, Rodvold KA et al (1994) The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 74:834–841 van der Zanden SY, Qiao X, Neefjes J (2021) New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS J 288:6095–6111. https://doi.org/10.1111/febs.15583 Shukla A, Hillegass JM, MacPherson MB et al (2010) Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer 9:1–13. https://doi.org/10.1186/1476-4598-9-314 Byron SA, Loch DC, Pollock PM (2012) Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells. Int J Gynecol Cancer 22:1517–1526. https://doi.org/10.1097/IGC.0b013e31826f6806 Sergei B, Pavel D, Aigul G et al (2020) Inhibition of FGFR2-signaling attenuates a homology-mediated dna repair in gist and sensitizes them to DNA-topoisomerase II inhibitors. Int J Mol Sci 21:352. https://doi.org/10.3390/ijms21010352 Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–2879. https://doi.org/10.1002/cncr.11407 Vishnu T, Veerabhadraiah M, Krishna Chaitanya V et al (2022) Design, synthesis and anticancer activity of 5-((2-(4-bromo/chloro benzoyl) benzofuran-5-yl) methyl)-2-((1-(substituted)-1H-1,2,3-triazol-4-yl)methoxy)benzaldehyde analogues. Mol Divers. https://doi.org/10.1007/s11030-022-10575-6 Vasava MS, Bhoi MN, Rathwa SK et al (2020) Benzimidazole: a milestone in the field of medicinal chemistry. Mini Rev Med Chem 20:532–565 Pérez-Villanueva J, Santos R, Hernández-Campos A et al (2011) Structure–activity relationships of benzimidazole derivatives as antiparasitic agents: Dual activity-difference (DAD) maps. Med Chem Commun 2:44–49. https://doi.org/10.1039/C0MD00159G Shingalapur RV, Hosamani KM, Keri RS, Hugar MH (2010) Derivatives of benzimidazole pharmacophore: Synthesis, anticonvulsant, antidiabetic and DNA cleavage studies. Eur J Med Chem 45:1753–1759. https://doi.org/10.1016/j.ejmech.2010.01.007 Siddiqui N, Alam MS, Sahu M et al (2016) Antidepressant, analgesic activity and SAR studies of substituted benzimidazoles. Asian J Pharm Res 6:170. https://doi.org/10.5958/2231-5691.2016.00024.1 Wang XJ, Xi MY, Fu JH et al (2012) Synthesis, biological evaluation and SAR studies of benzimidazole derivatives as H1-antihistamine agents. Chin Chem Lett 23:707–710. https://doi.org/10.1016/j.cclet.2012.04.020 Ganie AM, Dar AM, Khan FA, Dar BA (2019) Benzimidazole derivatives as potential antimicrobial and antiulcer agents: a mini review. Mini-Rev Med Chem 19:1292–1297. https://doi.org/10.2174/1381612824666181017102930 Jain A, Sharma R, Chaturvedi SC (2013) A rational design, synthesis, characterization, and antihypertensive activities of some new substituted benzimidazoles. Med Chem Res 22:4622–4632. https://doi.org/10.1007/s00044-012-0462-7 Kanwal A, Ahmad M, Aslam S et al (2019) Recent advances in antiviral benzimidazole derivatives: a mini review. Pharm Chem J 53:179–187. https://doi.org/10.1007/s11094-019-01976-3 Othman DIA, Hamdi A, Tawfik SS et al (2023) Identification of new benzimidazole-triazole hybrids as anticancer agents: multi-target recognition, in vitro and in silico studies. J Enzyme Inhib Med Chem 38:2166037 Ouahrouch A, Ighachane H, Taourirte M et al (2014) Benzimidazole-1,2,3-triazole hybrid molecules: synthesis and evaluation for antibacterial/antifungal activity. Arch Pharm (Weinheim) 347:748–755. https://doi.org/10.1002/ardp.201400142 Bansal Y, Silakari O (2014) Synthesis and pharmacological evaluation of polyfunctional benzimidazole-NSAID chimeric molecules combining anti-inflammatory, immunomodulatory and antioxidant activities. Arch Pharm Res 37:1426–1436 Syed A, Syeda A (2008) Spectrophotometric determination of certain benzimidazole proton pump inhibitors. Indian J Pharm Sci 70:507. https://doi.org/10.4103/0250-474X.44605 Pathare B, Bansode T (2021) Review- biological active benzimidazole derivatives. Results Chem 3:100200. https://doi.org/10.1016/j.rechem.2021.100200 Law CSW, Yeong KY (2021) Benzimidazoles in Drug Discovery: A Patent Review. ChemMedChem 16:1861–1877. https://doi.org/10.1002/cmdc.202100004 Ren Y, Wang Y, Li G et al (2021) Discovery of Novel Benzimidazole and Indazole Analogues as Tubulin Polymerization Inhibitors with Potent Anticancer Activities. J Med Chem 64:4498–4515. https://doi.org/10.1021/acs.jmedchem.0c01837 Akhtar MdJ, Yar MS, Sharma VK et al (2020) Recent Progress of Benzimidazole Hybrids for Anticancer Potential. Curr Med Chem 27:5970–6014. https://doi.org/10.2174/0929867326666190808122929 Wu K, Peng X, Chen M et al (2022) Recent progress of research on anti-tumor agents using benzimidazole as the structure unit. Chem Biol Drug Des 99:736–757. https://doi.org/10.1111/cbdd.14022 Ali AM, Tawfik SS, Mostafa AS, Massoud MAM (2022) Benzimidazole-based protein kinase inhibitors: Current perspectives in targeted cancer therapy. Chem Biol Drug Des 100:656–673. https://doi.org/10.1111/cbdd.14130 Tan YJ, Lee YT, Yeong KY et al (2018) Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer. Future Med Chem 10:2039–2057. https://doi.org/10.4155/fmc-2018-0052 Coleman RL, Fleming GF, Brady MF et al (2019) Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 381:2403–2415. https://doi.org/10.1056/NEJMoa1909707 Chen J, Li N, Liu B et al (2020) Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways. Life Sci 248:117469. https://doi.org/10.1016/j.lfs.2020.117469 Barman Balfour JA, Goa KL (2001) Bendamustine. Drugs 61:631–638. https://doi.org/10.2165/00003495-200161050-00009 Markham A, Keam SJ (2020) Selumetinib: first approval. Drugs 80:931–937. https://doi.org/10.1007/s40265-020-01331-x Woodfield SE, Zhang L, Scorsone KA et al (2016) Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer 16:172. https://doi.org/10.1186/s12885-016-2199-z Bryson HM, Wagstaff AJ (1996) Liarozole. Drugs Aging 9:478–484. https://doi.org/10.2165/00002512-199609060-00010 Akhter M, Habibullah S, Hasan SM et al (2011) Synthesis of some new 3,4-dihydro-2H-1,3-benzoxazines under microwave irradiation in solvent-free conditions and their biological activity. Med Chem Res 20:1147–1153. https://doi.org/10.1007/s00044-010-9451-x Kakkerla R, Marri S, Krishna MPSM et al (2018) Synthesis and biological evaluation of 3,4-dihydro-3-(3-methylisoxazol-5- yl)-2H-benzo[e] [1,3] oxazine derivatives as anticancer agents. Lett Org Chem. https://doi.org/10.2174/1570178614666170623121207 Mathew BP, Kumar A, Sharma S et al (2010) An eco-friendly synthesis and antimicrobial activities of dihydro-2H-benzo- and naphtho-1,3-oxazine derivatives. Eur J Med Chem 45:1502–1507. https://doi.org/10.1016/j.ejmech.2009.12.058 Kategaonkar AH, Sonar SS, Pokalwar RU et al (2010) An efficient synthesis of 3,4-dihydro-3-substituted-2H-naphtho[2,1-e] [1,3]o xazine derivatives catalyzed by zirconyl(IV) chloride and evaluation of its biological activities. Bull Korean Chem Soc 31:1657–1660. https://doi.org/10.5012/bkcs.2010.31.6.1657 Kang Y-G, Park C-Y, Shin H et al (2015) Synthesis and anti-tubercular activity of 2-nitroimidazooxazines with modification at the C-7 position as PA-824 analogs. Bioorg Med Chem Lett 25:3650–3653. https://doi.org/10.1016/j.bmcl.2015.06.060 Zhang H-J, Li Y-F, Cao Q et al (2017) Pharmacological evaluation of 9,10-dihydrochromeno[8,7-e] [1,3] oxazin-2(8H)-one derivatives as potent anti-inflammatory agent. Pharmacol Rep 69:419–425. https://doi.org/10.1016/j.pharep.2016.12.006 Chen C-L, Lee C-C, Liu F-L et al (2016) Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption. Eur J Med Chem 117:70–84. https://doi.org/10.1016/j.ejmech.2016.04.007 Gawali R, Trivedi J, Bhansali S et al (2018) Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors. Eur J Med Chem 157:310–319. https://doi.org/10.1016/j.ejmech.2018.07.067 Ho Y-J, Lu J-W, Ho L-J et al (2019) Anti-inflammatory and anti-osteoarthritis effects of Cm-02 and Ck-02. Biochem Biophys Res Commun 517:155–163. https://doi.org/10.1016/j.bbrc.2019.07.036 Ihmaid S, Al-Rawi J, Bradley C et al (2011) Synthesis, structural elucidation, DNA-PK inhibition, homology modelling and anti-platelet activity of morpholino-substituted-1,3-naphth-oxazines. Bioorg Med Chem 19:3983–3994. https://doi.org/10.1016/j.bmc.2011.05.032 Viegas-Junior C, Danuello A, da Silva BV et al (2007) Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem 14:1829–1852 Ivasiv V, Albertini C, Gonçalves AE et al (2019) Molecular hybridization as a tool for designing multitarget drug candidates for complex diseases. Curr Top Med Chem 19:1694–1711 Fraga CAM (2009) Drug hybridization strategies: before or after lead identification? Expert Opin Drug Discov 4:605–609 Nagamani M, Vishnu T, Jalapathi P, Srinivas M (2022) Molecular docking studies on COVID-19 and antibacterial evaluation of newly synthesized 4-(methoxymethyl)-1,2,3-triazolean analogues derived from (E)-1-phenyl-3-(2-(piperidin-1-yl)quinolin-3-yl) prop-2-en-1-one. J Iran Chem Soc 19:1049–1060. https://doi.org/10.1007/s13738-021-02365-y Veeranna D, Ramdas L, Ravi G et al (2022) Synthesis of 1,2,3-triazole tethered indole derivatives: evaluation of anticancer activity and molecular docking studies. ChemistrySelect 7:e202201758. https://doi.org/10.1002/slct.202201758 Liu Z, Liu Y, Zeng G et al (2018) Application of molecular docking for the degradation of organic pollutants in the environmental remediation: a review. Chemosphere 203:139–150. https://doi.org/10.1016/j.chemosphere.2018.03.179 Morris GM, Ruth H, Lindstrom W et al (2009) Software news and updates AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785–2791. https://doi.org/10.1002/jcc.21256 Trott O, Olson AJ (2009) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem NA-NA. https://doi.org/10.1002/jcc.21334 Friesner RA, Banks JL, Murphy RB et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy. J Med Chem 47:1739–1749. https://doi.org/10.1021/jm0306430 Dallakyan S, Olson AJ (2015) Small-molecule library screening by docking with PyRx. In: Hempel JE, Williams CH, Hong CC (eds) Methods in Molecular Biology. Springer, pp 243–250 Verdonk ML, Cole JC, Hartshorn MJ et al (2003) Improved protein-ligand docking using GOLD. Prot: Struct Funct Bioinform 52:609–623. https://doi.org/10.1002/prot.10465 Rarey M, Kramer B, Lengauer T, Klebe G (1996) A fast flexible docking method using an incremental construction algorithm. J Mol Biol 261:470–489. https://doi.org/10.1006/jmbi.1996.0477 Bitencourt-Ferreira G, de Azevedo WF (2019) Molegro Virtual Docker for Docking. In: Filgueira W, de Azevedo, (eds) Docking screens for drug discovery. Springer, New York Acharya R, Chacko S, Bose P et al (2019) Structure based multitargeted molecular docking analysis of selected furanocoumarins against breast cancer. Sci Rep 9:15743. https://doi.org/10.1038/s41598-019-52162-0 Yun C-H, Boggon TJ, Li Y et al (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11:217–227. https://doi.org/10.1016/j.ccr.2006.12.017 Seshacharyulu P, Ponnusamy MP, Haridas D et al (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15–31. https://doi.org/10.1517/14728222.2011.648617 Perike N, Edigi PK, Nirmala G, et al (2022) Synthesis, Anticancer Activity and Molecular Docking Studies of Hybrid Molecules Containing Indole-Thiazolidinedione-Triazole Moieties. ChemistrySelect. https://doi.org/10.1002/slct.202203778 Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:1–13 Martin YC (2005) A bioavailability score. J Med Chem 48:3164–3170. https://doi.org/10.1021/jm0492002 Lipinski CA (2004) Lead-and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 1:337–341 Ertl P, Schuffenhauer A (2009) Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J Cheminform 1:1–11 Sabhavath AK, Madderla S, Dharavath R et al (2022) Synthesis of 1,2,3-triazole-containing 2,3-dihydrofuran derivatives, evaluation of anticancer activity and molecular docking studies. ChemistrySelect 7:e202203847. https://doi.org/10.1002/slct.202203847 Ashok D, Thara G, Kumar BK et al (2023) Microwave-assisted synthesis, molecular docking studies of 1,2,3-triazole-based carbazole derivatives as antimicrobial, antioxidant and anticancer agents. RSC Adv 13:25–40. https://doi.org/10.1039/D2RA05960F